Universal Ibogaine Commences Development Plan At Kelburn In Preparation For Ibogaine Treatments And Provides Update On Drug Supply
CALGARY, AB, Feb. 2, 2022 /CNW/ – Universal Ibogaine Inc. (TSXV: IBO) (“UI” or the “Company“) a life sciences company with a mission to deliver medicalized ibogaine-centered addiction treatment, has initiated development plans at its Kelburn treatment facility in preparation for treatment protocol approval and commencement of ibogaine treatments.
What is Ibogaine?
Ibogaine is a plant derived neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state. Ibogaine has demonstrated particular effectiveness in treating opioid use disorder. When applied according to a strict safety protocol, ibogaine appears to eliminate the most painful symptoms of opioid withdrawal and provides a several month window free of drug cravings. Dr Alberto Sola, co-founder of Universal Ibogaine has administered more ibogaine treatments than any other doctor in the world.
Kelburn Addiction Treatment Center
Universal Ibogaine acquired the licensed and operational Kelburn Mental Health and Addiction Treatment facility in October of 2021. The facility sits on a destination 50 acre estate with a 9 hole golf course and currently operates as a traditional addiction treatment center.
Universal Ibogaine has undertaken plans to expand the facility to include traditional drug detox and to begin to incorporate the best in nuovo treatment modalities including Ketamine, Psilocybin and MDMA assisted psychotherapies.
Universal Ibogaine has commenced development plans to construct a stand alone ibogaine detox facility on the property in preparation for the completion of its proof of concept study with Health Canada.
Dr Ian Rabb – Chief Clinics Officer
Dr Ian Rabb of Universal Ibogaine stated: “In my 20 years of addiction treatment, I have not seen anything with the power and promise of ibogaine to break the cycle of addiction. When paired with a long term support plan, which we provide through our Kelburn facility, we expect to completely disrupt the addiction treatment model. Ibogaine is legal in Canada under the prescription drug list and requires a proof of safety trial through Health Canada. We are sitting on the edge of being able to tackle the opioid crisis head on.”
Drug Supply Update
Universal Ibogaine would also like to provide an update regarding the drug supply agreement with Psygen. The agreement was announced prematurely and contained some minor errors regarding the synthesis of the compound. As a result, the parties to the agreement have withdrawn.
UI is currently in negotiations with two alternative drug suppliers.
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based
drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe
through future licensing agreements. UI is concurrently developing a state of the art holistic addiction
treatment protocol at its Kelburn Clinic that, when paired with the ibogaine detox protocol, is intended to
revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS
THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information
is frequently characterized by words such as “plans”, “expect”, “project”, “intend”, “will”, “believe”,
“anticipate”, “estimate”, “scheduled”, ”potential”, or other similar words, or statements that certain events
or conditions “may”, “should” or ”could” occur. The forward-looking statements and information are based
on certain key expectations and assumptions made by UI. Although UI believes that the expectations
and assumptions on which the forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because UI can give no assurance that they will
prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve
inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due
to a number of factors and risks, which include, but are not limited to, risks that required regulatory
approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such
information, although considered reasonable by UI at the time of preparation, may prove to be incorrect
and readers are cautioned not to place undue reliance on forward-looking information, which speaks only
to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions
to forward-looking information contained herein to reflect events or circumstances that occur after the
date hereof or to reflect the occurrence of unanticipated events, except as may be required under
applicable securities laws.
For further information:
Investor Relations: Dugan Selkirk, IR Manager
Media Contact: Cathy Fernandes, Director – Marketing & Communications